Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

SAN FRANCISCO -- Older patients' survival in metastatic pancreatic cancer had a significant association with baseline ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12 per cent of men diagnosed with pancreatic cancer are alive five years after diagnosis; for women it is 14 per cent.

Fecal Pancreatic Elastase Testing MarketThe global fecal pancreatic elastase testing market is projected to experience significant growth, with an expected increase from USD 15,306.7 million in 2023 ...

Lisata Therapeutics shares dropped after a pancreatic cancer treatment trial didn't show significant improvement in patient survival. The stock fell 32% to $2.64 on Wednesday, losing all its gains ...